Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

A long-term antigen-spreading by novel cancer vaccine with hyaluronic acid nanogel accelerate the anti-neoplastic efficacy of cytotoxicity of infused TCR-T cells and altered neplastic microenvironment

Keiki Nagaharu, Fumiyasu Momose, Makiko Yamane et al. Nov 03, 2025 pp. 4130-4130 10.1182/blood-2025-4130

Abstract Background Recent progress of engineered T cells genetically modified to express tumor-specific T-cell receptors (TCR-T) has demons...

Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP

Changtai Tian, Luke Li, Mina Zheng et al. Nov 03, 2025 pp. 7223-7223 10.1182/blood-2025-7223

Abstract Introduction: According to Surveillance, Epidemiology, and End Results data, Diffuse Large B-Cell Lymphoma (DLBCL) is diagnosed at...

Collaborative outreach and education for management of bi-specific antibody treatment side effects in Relapsed/Refractory multiple myeloma (COMBAT-RRMM)

Jessica Lewis-Gonzalez, Yagnapriya Ammakola, Ankith Motkar et al. Nov 03, 2025 pp. 6427-6427 10.1182/blood-2025-6427

Abstract Introduction: Bi-specific antibodies (BsAbs) have emerged as a pivotal therapy for in relapsed or refractory di...

Single cell spatial transcriptomics reveals age-dependent cellular organization of mouse bone marrow

Christian Reardon-Lochbaum, Paolo Cadinu, Hao Zhang et al. Nov 03, 2025 pp. 3181-3181 10.1182/blood-2025-3181

Abstract Hematopoiesis occurs in the complex microenvironment of the bone marrow. This includes interactions between hematopoietic cells the...

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study

Junnan Li, Xin Wang, Shuangnian Xu et al. Nov 03, 2025 pp. 7544-7544 10.1182/blood-2025-7544

Abstract Background: Maintenance therapy plays a critical role to prolong remission and improve outcomes in multiple myeloma (MM). Ixazomib...

Point of care anti-CD19 CAR-T for autoimmune diseases

Ronit Marcus, Merav Lidar, Doron Rimar et al. Nov 03, 2025 pp. 5946-5946 10.1182/blood-2025-5946

Abstract Introduction: Anti-CD19 CAR-T cell therapy has revolutionized the treatment of B-cell malignancies. Given the c...

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Maher Albitar, Hong Zhang, Gustavo Rivero et al. Nov 03, 2025 pp. 5251-5251 10.1182/blood-2025-5251

Abstract Introduction: Despite multiple studies, the impact of IDH1 and IDH2 (IDH1/2) mutations on the overall biology and clinical outcome...

A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia

Salem Elias, Andrew Lu, FuGuo Liu et al. Nov 03, 2025 pp. 246-246 10.1182/blood-2025-246

Abstract Introduction While autologous CD19-directed CAR-T cell therapy has been highly efficacious in certain B cell malignancies, its effi...

Availability of blood products and transfusion practices in sub-saharan Africa for the management of patients with sickle cell disease: A survey in 16 countries.

Geoffrey Cheminet, Saliou Diop, Françoise Bernaudin et al. Nov 03, 2025 pp. 2966-2966 10.1182/blood-2025-2966

Abstract Background: Red blood cell (RBC) transfusions play a critical role in managing severe acute complications in patients with sickle c...

First report of novel biallelic KLF1 variants causing prenatal onset severe transfusion-dependent non-spherocytic hemolytic anemia in North America

Laila Alkhouli, Olga Latosh, Harry Layton Lesmana Nov 03, 2025 pp. 1102-1102 10.1182/blood-2025-1102

Abstract Kruppel-like factor 1 (KLF1) is an essential erythroid transcription factor that regulates globin gene switching and red blood cell...

Preliminary immunophenotyping in acquired Hemophilia A reveals an imbalanced immune activation landscape

Jian Baodan, Jiao Yingying, Fan Wenxuan et al. Nov 03, 2025 pp. 3089-3089 10.1182/blood-2025-3089

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disease characterized by the development of autoantibodies against the factor (F)V...

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies

Nikki Agarwal, Brenda Cooper, Molly Gallogly et al. Nov 03, 2025 pp. 5925-5925 10.1182/blood-2025-5925

Abstract Background: Chimeric antigen receptor (CAR) T cells have revolutionized care for lymphoid malignancies but continue to present chal...

Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature

Ahmed Qaedi, Tanja Dudenbostel Nov 03, 2025 pp. 7244-7244 10.1182/blood-2025-7244

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive non-Hodgkin lymphoma, known for its invasive natu...

Disparities and trends in hospice facility deaths among leukemia patients

Alaa Mahmoud, Ibrahim Hassan, Khaled Elhusseiny et al. Nov 03, 2025 pp. 2852-2852 10.1182/blood-2025-2852

Abstract Background Patients with advanced or refractory hematologic malignancies experience a distinct disease course w...

Detecting lineage-specific regulatory activity and stemness retention in single-cell multiomics of human hematopoiesis

Cailin Jordan, Dominik Otto, Jacob Greene et al. Nov 03, 2025 pp. 6119-6119 10.1182/blood-2025-6119

Abstract Introduction: The prevalence of epigenetic regulator mutations in clonal hematopoiesis and hematologic malignancies highlights the...

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Antonio Solana-Altabella, Antonio Moscardó, Pilar Lloret Madrid et al. Nov 03, 2025 pp. 1694-1694 10.1182/blood-2025-1694

Abstract Introduction FMS-like tyrosine kinase 3 (FLT3) plays a critical role in hematopoiesis. Circulating levels of its ligand, the solubl...

Myeloproliferative neoplasm thrombosis risk characterized by MerTK biomarker

Nithita Nanthatanti, Kaelyn Chen, Paul Krenik et al. Nov 03, 2025 pp. 3821-3821 10.1182/blood-2025-3821

Abstract Introduction Thrombosis remains a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). Identi...

G-CSF receptor is a signaling node linking thrombo-inflammation to vaso-occlusion in sickle cell disease: Target for a new phase 2 trial

Gregory Kato, Tomasz Kaminski, Paolo Rossato et al. Nov 03, 2025 pp. 838-838 10.1182/blood-2025-838

Abstract Introduction Granulocyte-colony stimulating factor (G-CSF) administration is known to induce severe vaso-occlusive crisis (VOC) in...

Novel PF4/heparin complexes drive platelet activation in heparin-induced thrombocytopenia

Daniel Villalobos, Renren Wen, Demin Wang et al. Nov 03, 2025 pp. 3097-3097 10.1182/blood-2025-3097

Abstract Understanding the interaction between platelet factor 4 (PF4) and heparin is essential for elucidating the pathogenesis of heparin-...

Optimizing multiple myeloma assessment for newly diagnosed patients across a large, 33 hospital healthcare system: A mixed methods analysis

Bradley Hunter, Heather Black, Jacob Wilkes et al. Nov 03, 2025 pp. 2637-2637 10.1182/blood-2025-2637

Abstract Introduction Only 20-50% of patients with multiple myeloma (MM) who are transplant eligible (TE) undergo autologous stem cell trans...

A novel CD20-conjugated γδ T cell therapy via unnatural sugar-mediated chemical modification for the treatment of EBV-PTLD

Xuying Pei, Haichuan Zhu, Bo Cheng et al. Nov 03, 2025 pp. 2353-2353 10.1182/blood-2025-2353

Abstract Background: Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complicat...

Effects of race, sex, marital status, and urban/rural setting on survival in patients with acute myeloid leukemia

Lisa Liu, Alvaro Zevallos Barboza, Samah Nassereddine Nov 03, 2025 pp. 8204-8204 10.1182/blood-2025-8204

Abstract Background: Demographic factors such as race, sex, marital status, and rural-urban setting have been shown to b...

Impairing NAD+ synthesis is a powerful tool to increase the efficacy of the BTK inhibitor ibrutinib in Waldenström's macroglobulinemia.

Abhishek Banerjee, Elke Runge, Jasmin Mark et al. Nov 03, 2025 pp. 6818-6818 10.1182/blood-2025-6818

Abstract Waldenström's Macroglobulinemia (WM) is a rare indolent B-cell lymphoma characterized by the infiltration of bone marrow with lymph...

Disease stage-specific mutational landscape in essential thrombocythemia and prognostic correlates: A Mayo Clinic study of 500 NGS-informative cases

Merry Nakhleh, Rong He, Priyansh Faldu et al. Nov 03, 2025 pp. 3799-3799 10.1182/blood-2025-3799

Abstract Background In our first exploration of mutations in essential thrombocythemia (ET; N=183), we described somatic variants other than...

TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia

Jeevitha D'Souza, Camille Leung, Aishwarya Ballapuram et al. Nov 03, 2025 pp. 3470-3470 10.1182/blood-2025-3470

Abstract Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy associated with poor outcomes and limited tre...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page